ACHL (Achilles Therapeutics) Common Stock : $0.05 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Common Stock?

Achilles Therapeutics's quarterly common stock stayed the same from Mar. 2024 ($0.05 Mil) to Jun. 2024 ($0.05 Mil) and stayed the same from Jun. 2024 ($0.05 Mil) to Sep. 2024 ($0.05 Mil).

Achilles Therapeutics's annual common stock stayed the same from Dec. 2021 ($0.05 Mil) to Dec. 2022 ($0.05 Mil) and stayed the same from Dec. 2022 ($0.05 Mil) to Dec. 2023 ($0.05 Mil).

Achilles Therapeutics Common Stock Historical Data

The historical data trend for Achilles Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Common Stock Chart

Achilles Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

0.01

0.05

Achilles Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															0.05	0.05	0.05	0.05	0.05

Achilles Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Achilles Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.achillestx.com

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.